Mortality within the 6-months following MI
| Group 1 (sDMARD) | Group 2 (on TNFi+90 days lag at time of MI) | Group 3 (exposure to TNFi more than 90 days prior to MI) | |
|---|---|---|---|
| Total number of verified first MIs identified from BSRBR-RA and/or MINAP | 58 | 194 | 82 |
| Deaths within 6 months, n (%) | 12 (21) | 25 (13) | 40 (48) |
| Unadjusted OR (95% CI) | Referent | 0.61 (0.28 to 1.31) | 2.84 (1.33 to 6.04) |
| OR adjusted for age and gender (95% CI) | 0.68 (0.31 to 1.47) | 3.07 (1.42 to 6.62) | |
| Number of verified first MIs with MINAP data (% total verified MIs) | 35 (60) | 108 (56) | 55 (67) |
| Deaths within 6 months, n (%) | 2 (6) | 3 (3) | 11 (20) |
| Median MG score (IQR) | 108 (81 to 131) | 100 (84 to 120) | 112 (93 to 129) |
| Unadjusted OR (95% CI) | Referent | 0.47 (0.08 to 2.94) | 4.13 (0.86 to 19.89) |
| OR adjusted for age and gender (95% CI) | 0.51 (0.08 to 3.21) | 4.07 (0.82 to 20.07) | |
| OR adjusted for MG score (95% CI) | 0.47 (0.06 to 3.45) | 5.40 (0.93 to 31.18) |
BSRBR-RA, British Society for Rheumatology Biologics Register for Rheumatoid Arthritis; MG score, modified Global Registry of Acute Coronary Events score; MI, myocardial infarction; MINAP, Myocardial Ischaemia National Audit Project; sDMARD, synthetic disease modifying anti-rheumatic drug; TNFi, tumour necrosis factor α inhibitor.